KPV vs Thymosin Beta-4
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
KPV
KPV is a C-terminal tripeptide fragment (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH). Despite its small size — just three amino acids — it retains the anti-inflammatory core activity of its parent molecule without the melanogenic effects. It is one of the most researched peptides for gut inflammation, IBD, and intestinal permeability, with the ability to act locally in the gut when administered orally.
Full profileThymosin Beta-4
Thymosin Beta-4 (TB4) is the full-length 43-amino acid peptide produced naturally in high concentrations in platelets, wound fluid, and regenerating tissue. It is the parent molecule from which the popular TB-500 research peptide (the 17-23 fragment Ac-LKKTETQ) is derived. TB4 promotes actin polymerization, accelerates wound healing, reduces inflammation, and supports cardiac and neurological repair in preclinical models.
Full profile| KPV | Thymosin Beta-4 | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Lys-Pro-Val, Alpha-MSH C-terminal tripeptide | TB4, Tβ4, Tβ4 full-length |
| Evidence | Research-stage | Investigational (in trials) |
| Dosing range | 250mcg–1000mcg mcg, Once or twice daily | 500mcg–2000mcg mcg, 2–3x weekly |
| Administration | Subcutaneous injection, Oral (encapsulated — for gut-specific delivery), Intranasal | Subcutaneous injection, Intramuscular injection, Intravenous (clinical studies only) |
| Key side effects | Generally well-tolerated, Mild injection site irritation, Transient headache (uncommon), No melanogenic effects (does not cause tanning unlike full α-MSH) | Injection site discomfort (mild), Transient fatigue post-injection, Headache (uncommon), Theoretically may accelerate growth of pre-existing malignant tumors (promotes angiogenesis and cell migration — use with caution) |
| Cited sources | 3 references | 3 references |
Key differences
- Evidence level differs: KPV is research-stage, while Thymosin Beta-4 is investigational (in trials).
- Administration: KPV — Subcutaneous injection, Oral (encapsulated — for gut-specific delivery), Intranasal; Thymosin Beta-4 — Subcutaneous injection, Intramuscular injection, Intravenous (clinical studies only).
- Frequency: KPV is typically Once or twice daily; Thymosin Beta-4 is 2–3x weekly.
How each works
KPV
KPV exerts anti-inflammatory effects through melanocortin receptor-independent mechanisms as well as via MC1R and MC3R activation. It downregulates NF-κB, inhibits pro-inflammatory cytokines (TNF-α, IL-1β, IL-8), and reduces neutrophil infiltration in colonic tissue. Uniquely for a peptide, KPV is acid-stable enough to survive gastric transit and reach the intestinal mucosa intact, making oral delivery viable for gut-targeted applications — a significant advantage over most injectable-only peptides.
Thymosin Beta-4
TB4's primary mechanism involves sequestering G-actin monomers (via its LKKTET actin-binding domain) to regulate actin cytoskeleton dynamics — critical for cell migration, wound closure, and tissue remodeling. Clinical trials have evaluated TB4 for corneal wound healing (Phase 2), pressure ulcers, and cardiac repair after MI. The FACT trial investigated TB4 in patients with ischemic heart failure, showing trends toward improved cardiac function. Anti-inflammatory effects are mediated partly through NF-κB pathway downregulation.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.